葵花药业(002737.SZ)：拟立项开展中药同名同方药研发、化药仿制药视同一致性评价项目研发等工作

Group 1 - The company, Kew Flower Pharmaceutical (002737.SZ), announced a plan to invest up to 50 million yuan for the development of traditional Chinese medicine with the same name and formula, generic drug projects aligned with consistency evaluation, and research to expand indications for existing products [1] - The management has been authorized to oversee the progress and specific matters related to the project development [1] - This initiative aims to enrich the product pipeline and strengthen the company's long-term development momentum [1]